Skip to content
  • Who We Are
    • About Us
    • Our Facility
    • Careers
  • AAV Capabilities
  • Who We Serve
    • Researchers
    • Foundations
    • Biotechs
    • Pharmaceutical Companies
  • Resources
    • Insights
    • News
    • Events
  • Contact Us
News

Infantile Krabbe disease (0–12 months), progression, and recommended endpoints for clinical trials

November 5, 2024

Share:

  • Share on Facebook
  • Share on X
  • Share on LinkedIn
News
  • About Forge
  • Press Releases
  • Our Facility
  • Careers
  • AAV Manufacturing
  • FUEL™ AAV Platform
  • Blaze Vector Production
  • Viral Vector Services
  • Services for Foundations
  • Services for Biotechs
  • Services for Researchers
  • Services for Pharma Companies
Contact Us
  • © 2026 Forge Biologics
  • Terms & Conditions
  • Cookie Policy
  • Privacy Policy
  • Manage Cookies
  • Media Kit